Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VACCINEX, INC.VCNX · Entity 9673 | Director · President and CEO · 10% owner | November 14, 2024 | November 18, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VACCINEX, INC.
Report date November 14, 2024 · Filed November 18, 2024
Jointly reported with Vaccinex (Rochester), L.L.C.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Vaccinex (Rochester), L.L.C. | 297,941 |
Reported balance
After 2024-11-14 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2024-11-14 · Grant · Acquired 46,153 · Balance 297,941 F2: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 1,580 |
Reported balance
Holding disclosure · report date 2024-11-14 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,580 |
| Common StockSEC Table I · non-derivative | IndirectBy Jeremy C. Zauderer Trust | 1,016 |
Reported balance
Holding disclosure · report date 2024-11-14 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,016 F1: Dr. Zauderer exercises voting control over shares held by this trust and disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Jordan M. Zauderer Trust | 1,011 |
Reported balance
Holding disclosure · report date 2024-11-14 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,011 F1: Dr. Zauderer exercises voting control over shares held by this trust and disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.64 · Expires 2029-09-18 | IndirectBy Vaccinex (Rochester), L.L.C. | 170,475 |
Reported balance
Holding disclosure · report date 2024-11-14 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 170,475 F2: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1,491.00 · Expires 2025-12-23 | Direct | 15 |
Reported balance
Holding disclosure · report date 2024-11-14 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 15 F3: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1,402.80 · Expires 2025-02-24 | Direct | 135 |
Reported balance
Holding disclosure · report date 2024-11-14 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 135 F3: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $615.30 · Expires 2031-04-02 | Direct | 66 |
Reported balance
Holding disclosure · report date 2024-11-14 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 66 F4: This option vests one-fourth on each of the first four anniversaries of the April 2, 2021 grant date, except as otherwise provided in the award notice. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $270.90 · Expires 2032-04-01 | Direct | 133 |
Reported balance
Holding disclosure · report date 2024-11-14 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 133 F5: This option vests one-fourth on each of the first four anniversaries of the April 1, 2022 grant date, except as otherwise provided in the award notice. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $92.26 · Expires 2028-03-30 | Direct | 266 |
Reported balance
Holding disclosure · report date 2024-11-14 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 266 F6: This option vests one-fourth on each of the first four anniversaries of the March 31, 2023 grant date, except as otherwise provided in the award notice. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.21 · Expires 2034-03-21 | Direct | 1,877 |
Reported balance
Holding disclosure · report date 2024-11-14 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 1,877 F7: This option vests one-fourth on each of the first four anniversaries of the March 21, 2024 grant date, except as otherwise provided in the award notice. |
Filing footnotes · ownership attribution and instrument terms
F1: Dr. Zauderer exercises voting control over shares held by this trust and disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein.
F2: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F3: Exercisable in full as of the date of this report.
F4: This option vests one-fourth on each of the first four anniversaries of the April 2, 2021 grant date, except as otherwise provided in the award notice.
F5: This option vests one-fourth on each of the first four anniversaries of the April 1, 2022 grant date, except as otherwise provided in the award notice.
F6: This option vests one-fourth on each of the first four anniversaries of the March 31, 2023 grant date, except as otherwise provided in the award notice.
F7: This option vests one-fourth on each of the first four anniversaries of the March 21, 2024 grant date, except as otherwise provided in the award notice.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 14, 2024 Filed Nov 18, 2024 16:05 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantCommon Stock | 46,153 | $3.25 | $149,997.25 |
DisclosureSEC source: 0001062993-24-019265 · form4.xml · nonDerivative · entry 4 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vaccinex (Rochester), L.L.C. Disclosed balance after: 297,941 F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 18, 2024 Filed Sep 20, 2024 16:14 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantWarrant (Right to Buy) · Derivative | 170,475 | $0.13 Strike: $5.64 | $21,309.38 |
DisclosureSEC source: 0001062993-24-016842 · form4.xml · derivative · entry 12 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vaccinex (Rochester), L.L.C. Disclosed balance after: 170,475 Underlying: Common Stock · 170,475 shares Expires 2029-09-18 F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 18, 2024 Filed Sep 20, 2024 16:14 UTC | VACCINEX, INC. VCNX · Entity 9673 | Exercise / conversionWarrant (Right to Buy) · Derivative | 35,715 | $0.00 Strike: $5.64 | $0.00 |
DisclosureSEC source: 0001062993-24-016842 · form4.xml · derivative · entry 11 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vaccinex (Rochester), L.L.C. Disclosed balance after: 0 Underlying: Common Stock · 35,715 shares Expires 2028-10-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: This warrant was originally reported on Form 4 with an exercise price of $14.00. Pursuant to the Warrant Inducement Agreement, the exercise price of this warrant was adjusted to $5.636. F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 18, 2024 Filed Sep 20, 2024 16:14 UTC | VACCINEX, INC. VCNX · Entity 9673 | Exercise / conversionWarrant (Right to Buy) · Derivative | 9,768 | $0.00 Strike: $5.64 | $0.00 |
DisclosureSEC source: 0001062993-24-016842 · form4.xml · derivative · entry 10 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vaccinex (Rochester), L.L.C. Disclosed balance after: 0 Underlying: Common Stock · 9,768 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: This warrant was originally reported on Form 4 with an exercise price of $32.76. Pursuant to the Warrant Inducement Agreement, the exercise price of this warrant was adjusted to $5.636. F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 18, 2024 Filed Sep 20, 2024 16:14 UTC | VACCINEX, INC. VCNX · Entity 9673 | Exercise / conversionWarrant (Right to Buy) · Derivative | 29,557 | $0.00 Strike: $5.64 | $0.00 |
DisclosureSEC source: 0001062993-24-016842 · form4.xml · derivative · entry 9 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vaccinex (Rochester), L.L.C. Disclosed balance after: 0 Underlying: Common Stock · 29,557 shares Expires 2029-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: This warrant was originally reported on Form 4 with an exercise price of $14.00. Pursuant to the Warrant Inducement Agreement, the exercise price of this warrant was adjusted to $5.636. F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 18, 2024 Filed Sep 20, 2024 16:14 UTC | VACCINEX, INC. VCNX · Entity 9673 | Exercise / conversionWarrant (Right to Buy) · Derivative | 38,610 | $0.00 Strike: $5.64 | $0.00 |
DisclosureSEC source: 0001062993-24-016842 · form4.xml · derivative · entry 8 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vaccinex (Rochester), L.L.C. Disclosed balance after: 0 Underlying: Common Stock · 38,610 shares Expires 2029-03-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: This warrant was originally reported on Form 4 with an exercise price of $7.64. Pursuant to a warrant inducement agreement by and between the issuer and Vaccinex (Rochester) L.L.C. dated September 17, 2024 (the "Warrant Inducement Agreement"), the exercise price of this warrant was adjusted to $5.636. F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 18, 2024 Filed Sep 20, 2024 16:14 UTC | VACCINEX, INC. VCNX · Entity 9673 | Exercise / conversionCommon Stock | 35,715 | $5.64 | $201,289.74 |
DisclosureSEC source: 0001062993-24-016842 · form4.xml · nonDerivative · entry 7 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vaccinex (Rochester), L.L.C. Disclosed balance after: 251,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: This warrant was originally reported on Form 4 with an exercise price of $14.00. Pursuant to the Warrant Inducement Agreement, the exercise price of this warrant was adjusted to $5.636. F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 18, 2024 Filed Sep 20, 2024 16:14 UTC | VACCINEX, INC. VCNX · Entity 9673 | Exercise / conversionCommon Stock | 9,768 | $5.64 | $55,052.45 |
DisclosureSEC source: 0001062993-24-016842 · form4.xml · nonDerivative · entry 6 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vaccinex (Rochester), L.L.C. Disclosed balance after: 216,073 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: This warrant was originally reported on Form 4 with an exercise price of $32.76. Pursuant to the Warrant Inducement Agreement, the exercise price of this warrant was adjusted to $5.636. F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 18, 2024 Filed Sep 20, 2024 16:14 UTC | VACCINEX, INC. VCNX · Entity 9673 | Exercise / conversionCommon Stock | 29,557 | $5.64 | $166,583.25 |
DisclosureSEC source: 0001062993-24-016842 · form4.xml · nonDerivative · entry 5 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vaccinex (Rochester), L.L.C. Disclosed balance after: 206,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: This warrant was originally reported on Form 4 with an exercise price of $14.00. Pursuant to the Warrant Inducement Agreement, the exercise price of this warrant was adjusted to $5.636. F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 18, 2024 Filed Sep 20, 2024 16:14 UTC | VACCINEX, INC. VCNX · Entity 9673 | Exercise / conversionCommon Stock | 38,610 | $5.64 | $217,605.96 |
DisclosureSEC source: 0001062993-24-016842 · form4.xml · nonDerivative · entry 4 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vaccinex (Rochester), L.L.C. Disclosed balance after: 176,748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: This warrant was originally reported on Form 4 with an exercise price of $7.64. Pursuant to a warrant inducement agreement by and between the issuer and Vaccinex (Rochester) L.L.C. dated September 17, 2024 (the "Warrant Inducement Agreement"), the exercise price of this warrant was adjusted to $5.636. F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 20:54 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantWarrant (Right to Buy) · Derivative | 38,610 | $7.77 Strike: $7.64 | $299,999.70 |
DisclosureSEC source: 0001062993-24-007661 · form4.xml · derivative · entry 5 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vaccinex (Rochester), L.L.C. Disclosed balance after: 38,610 Underlying: Common Stock · 38,610 shares Expires 2029-03-28 F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 20:54 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantCommon Stock | 38,610 | $7.77 | $299,999.70 |
DisclosureSEC source: 0001062993-24-007661 · form4.xml · nonDerivative · entry 4 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vaccinex (Rochester), L.L.C. Disclosed balance after: 138,138 F2 · shares: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. F2 · balance_after: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| March 21, 2024 Filed May 14, 2024 16:34 UTC Amendment | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 1,877 | $0.00 Strike: $8.21 | $0.00 |
DisclosureSEC source: 0001062993-24-010185 · form4a.xml · derivative · entry 1 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,877 Underlying: Common Stock · 1,877 shares Expires 2034-03-21 F1 · derivative.exercise_price: Due to an administrative error, the original Form 4 mistakenly listed the transaction date as March 20, 2024. The transaction actually occurred on March 21, 2024. Accordingly, the exercise price of the stock option is $8.21 per share, as opposed to the exercise price of $9.15 that was listed in the original Form 4. F1 · date: Due to an administrative error, the original Form 4 mistakenly listed the transaction date as March 20, 2024. The transaction actually occurred on March 21, 2024. Accordingly, the exercise price of the stock option is $8.21 per share, as opposed to the exercise price of $9.15 that was listed in the original Form 4. F2 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 21, 2024 grant date. F3 · derivative.expiration_date: Due to an administrative error, the original Form 4 mistakenly listed the stock option expiration date as March 20, 2029. The expiration date is actually March 21, 2034. Read SEC document |
| March 20, 2024 Filed Mar 22, 2024 16:31 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 1,877 | $0.00 Strike: $9.15 | $0.00 |
DisclosureSEC source: 0001062993-24-006957 · form4.xml · derivative · entry 15 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,877 Underlying: Common Stock · 1,877 shares Expires 2029-03-20 F7 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 20, 2024 grant date. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 16:34 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantWarrant (Right to Buy) · Derivative | 413,793 | $0.73 Strike: $1.00 | $299,999.93 |
DisclosureSEC source: 0001062993-24-002770 · form4.xml · derivative · entry 5 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vaccinex (Rochester), L.L.C. Disclosed balance after: 413,793 Underlying: Common Stock · 413,793 shares Expires 2029-02-08 F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 16:34 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantCommon Stock | 413,793 | $0.73 | $299,999.93 |
DisclosureSEC source: 0001062993-24-002770 · form4.xml · nonDerivative · entry 4 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vaccinex (Rochester), L.L.C. Disclosed balance after: 1,393,392 F2 · shares: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. F2 · balance_after: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| November 02, 2023 Filed Nov 3, 2023 16:29 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantWarrant (Right to Buy) · Derivative | 136,752 | $0.13 Strike: $2.34 | $17,094.00 |
DisclosureSEC source: 0001062993-23-020103 · form4.xml · derivative · entry 5 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vaccinex (Rochester), L.L.C. Disclosed balance after: 136,752 Underlying: Common Stock · 136,752 shares Expires 2028-11-02 F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| October 04, 2023 Filed Oct 5, 2023 16:31 UTC | VACCINEX, INC. VCNX · Entity 9673 | PurchaseCommon Stock | 5,000 | $0.97 | $4,865.00 |
DisclosureSEC source: 0001062993-23-019063 · form4.xml · nonDerivative · entry 6 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,116 F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9501 to $0.9898, inclusive. Mr. Zauderer undertakes to provide Vaccinex, Inc., any security holder of Vaccinex, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| October 03, 2023 Filed Oct 5, 2023 16:31 UTC | VACCINEX, INC. VCNX · Entity 9673 | PurchaseWarrant (Right to Buy) · Derivative | 500,000 | $1.00 Strike: $1.00 | $500,000.00 |
DisclosureSEC source: 0001062993-23-019063 · form4.xml · derivative · entry 7 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vaccinex (Rochester), L.L.C. Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2028-10-03 F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| October 03, 2023 Filed Oct 5, 2023 16:31 UTC | VACCINEX, INC. VCNX · Entity 9673 | PurchaseCommon Stock | 5,000 | $0.93 | $4,650.00 |
DisclosureSEC source: 0001062993-23-019063 · form4.xml · nonDerivative · entry 5 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,116 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9265 to $0.9399, inclusive. Mr. Zauderer undertakes to provide Vaccinex, Inc., any security holder of Vaccinex, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| October 03, 2023 Filed Oct 5, 2023 16:31 UTC | VACCINEX, INC. VCNX · Entity 9673 | PurchaseCommon Stock | 500,000 | $1.00 | $500,000.00 |
DisclosureSEC source: 0001062993-23-019063 · form4.xml · nonDerivative · entry 4 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vaccinex (Rochester), L.L.C. Disclosed balance after: 979,599 F2 · balance_after: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 22, 2023 Filed Sep 25, 2023 16:12 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantCommon Stock | 2,051,282 | $0.16 | $319,999.99 |
DisclosureSEC source: 0001062993-23-018438 · form4.xml · nonDerivative · entry 4 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Vaccinex (Rochester), L.L.C. Disclosed balance after: 7,193,973 F2 · shares: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. F2 · balance_after: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 16:31 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 56,000 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0001062993-23-008320 · form4.xml · derivative · entry 12 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 56,000 shares Expires 2028-03-30 F7 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 31, 2023 grant date. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 16:31 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantCommon Stock | 731,707 | $0.41 | $299,999.87 |
DisclosureSEC source: 0001062993-23-008320 · form4.xml · nonDerivative · entry 4 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Vaccinex (Rochester), L.L.C. Disclosed balance after: 5,142,691 F2 · shares: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. F2 · balance_after: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| December 06, 2022 Filed Dec 7, 2022 16:30 UTC | VACCINEX, INC. VCNX · Entity 9673 | OtherCommon Stock | 3,988 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-023491 · form4.xml · nonDerivative · entry 1 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,736 Read SEC document |
| November 23, 2022 Filed Nov 28, 2022 16:35 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantCommon Stock | 1,511,430 | $0.53 | $799,999.90 |
DisclosureSEC source: 0001062993-22-022815 · form4.xml · nonDerivative · entry 4 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Vaccinex (Rochester), L.L.C. Disclosed balance after: 4,410,984 F2 · shares: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. F2 · balance_after: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 16:34 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001062993-22-009448 · form4.xml · derivative · entry 11 Zauderer Maurice · CIK 0001747753 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2032-04-01 F7 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the April 1, 2022 grant date. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 16:23 UTC | VACCINEX, INC. VCNX · Entity 9673 | PurchaseCommon Stock | 1,801,801 | $1.11 | $1,999,999.11 |
DisclosureSEC source: 0001062993-22-001866 · form4.xml · nonDerivative · entry 4 Zauderer Maurice · CIK 0001747753 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Vaccinex (Rochester), L.L.C. Disclosed balance after: 2,899,554 F2 · shares: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. F2 · balance_after: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| April 02, 2021 Filed Apr 2, 2021 16:27 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0000891839-21-000100 · edgar.xml · derivative · entry 10 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2031-04-02 F6 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the April 2, 2021 grant date. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 16:25 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 28,400 | $0.00 Strike: $6.68 | $0.00 |
DisclosureSEC source: 0000891839-20-000054 · edgar.xml · derivative · entry 9 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,400 Underlying: Common Stock · 28,400 shares Expires 2025-02-24 F5 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the February 25, 2020 grant date. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 16:23 UTC | VACCINEX, INC. VCNX · Entity 9673 | PurchaseCommon Stock | 98,231 | $5.09 | $499,995.79 |
DisclosureSEC source: 0000891839-20-000032 · edgar.xml · nonDerivative · entry 4 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Vaccinex (Rochester), L.L.C. Disclosed balance after: 1,097,753 F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| July 30, 2019 Filed Jul 31, 2019 16:31 UTC | VACCINEX, INC. VCNX · Entity 9673 | PurchaseCommon Stock | 183,824 | $4.08 | $750,001.92 |
DisclosureSEC source: 0000891839-19-000143 · edgar.xml · nonDerivative · entry 4 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Vaccinex (Rochester), L.L.C. Disclosed balance after: 999,522 F2 · ownership.nature: Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 17:04 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $4.29 | $0.00 |
DisclosureSEC source: 0000891839-19-000052 · edgar.xml · derivative · entry 9 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2024-03-14 F5 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 15, 2019 grant date. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 16:49 UTC | VACCINEX, INC. VCNX · Entity 9673 | ConversionSeries D Convertible Preferred Stock · Derivative | 8,157,067 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-18-000926 · edgar.xml · derivative · entry 8 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Vaccinex (Rochester), L.L.C. Disclosed balance after: 0 Underlying: Common Stock · 815,698 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The reported securities converted into shares of Common Stock on a 1-for-10 basis immediately prior to the consummation of the Issuer's initial public offering. F4 · price: The reported securities converted into shares of Common Stock on a 1-for-10 basis immediately prior to the consummation of the Issuer's initial public offering. F4 · derivative.exercise_date: The reported securities converted into shares of Common Stock on a 1-for-10 basis immediately prior to the consummation of the Issuer's initial public offering. F4 · derivative.expiration_date: The reported securities converted into shares of Common Stock on a 1-for-10 basis immediately prior to the consummation of the Issuer's initial public offering. F2 · ownership.nature: Mr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 16:49 UTC | VACCINEX, INC. VCNX · Entity 9673 | ConversionSeries B Convertible Preferred Stock · Derivative | 581,577 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-18-000926 · edgar.xml · derivative · entry 7 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Jordan M. Zauderer Trust Disclosed balance after: 0 Underlying: Common Stock · 95,448 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The reported securities converted into shares of Common Stock on a 0.1641-for-1 basis immediately prior to the consummation of the Issuer's initial public offering. F3 · price: The reported securities converted into shares of Common Stock on a 0.1641-for-1 basis immediately prior to the consummation of the Issuer's initial public offering. F3 · derivative.exercise_date: The reported securities converted into shares of Common Stock on a 0.1641-for-1 basis immediately prior to the consummation of the Issuer's initial public offering. F3 · derivative.expiration_date: The reported securities converted into shares of Common Stock on a 0.1641-for-1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · ownership.nature: Maurice Zauderer exercises voting control over shares held by this trust and disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 16:49 UTC | VACCINEX, INC. VCNX · Entity 9673 | ConversionSeries B Convertible Preferred Stock · Derivative | 581,577 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-18-000926 · edgar.xml · derivative · entry 6 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Jeremy C. Zauderer Trust Disclosed balance after: 0 Underlying: Common Stock · 95,448 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The reported securities converted into shares of Common Stock on a 0.1641-for-1 basis immediately prior to the consummation of the Issuer's initial public offering. F3 · price: The reported securities converted into shares of Common Stock on a 0.1641-for-1 basis immediately prior to the consummation of the Issuer's initial public offering. F3 · derivative.exercise_date: The reported securities converted into shares of Common Stock on a 0.1641-for-1 basis immediately prior to the consummation of the Issuer's initial public offering. F3 · derivative.expiration_date: The reported securities converted into shares of Common Stock on a 0.1641-for-1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · ownership.nature: Maurice Zauderer exercises voting control over shares held by this trust and disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 16:49 UTC | VACCINEX, INC. VCNX · Entity 9673 | ConversionSeries B Convertible Preferred Stock · Derivative | 569,993 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-18-000926 · edgar.xml · derivative · entry 5 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 93,547 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The reported securities converted into shares of Common Stock on a 0.1641-for-1 basis immediately prior to the consummation of the Issuer's initial public offering. F3 · price: The reported securities converted into shares of Common Stock on a 0.1641-for-1 basis immediately prior to the consummation of the Issuer's initial public offering. F3 · derivative.exercise_date: The reported securities converted into shares of Common Stock on a 0.1641-for-1 basis immediately prior to the consummation of the Issuer's initial public offering. F3 · derivative.expiration_date: The reported securities converted into shares of Common Stock on a 0.1641-for-1 basis immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 16:49 UTC | VACCINEX, INC. VCNX · Entity 9673 | ConversionCommon Stock | 815,698 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-18-000926 · edgar.xml · nonDerivative · entry 4 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Vaccinex (Rochester), L.L.C. Disclosed balance after: 815,698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The reported securities converted into shares of Common Stock on a 1-for-10 basis immediately prior to the consummation of the Issuer's initial public offering. F2 · ownership.nature: Mr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 16:49 UTC | VACCINEX, INC. VCNX · Entity 9673 | ConversionCommon Stock | 95,448 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-18-000926 · edgar.xml · nonDerivative · entry 3 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Jordan M. Zauderer Trust Disclosed balance after: 212,161 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The reported securities converted into shares of Common Stock on a 0.1641-for-1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · ownership.nature: Maurice Zauderer exercises voting control over shares held by this trust and disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 16:49 UTC | VACCINEX, INC. VCNX · Entity 9673 | ConversionCommon Stock | 95,448 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-18-000926 · edgar.xml · nonDerivative · entry 2 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Jeremy C. Zauderer Trust Disclosed balance after: 213,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The reported securities converted into shares of Common Stock on a 0.1641-for-1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · ownership.nature: Maurice Zauderer exercises voting control over shares held by this trust and disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 16:49 UTC | VACCINEX, INC. VCNX · Entity 9673 | ConversionCommon Stock | 93,547 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-18-000926 · edgar.xml · nonDerivative · entry 1 Zauderer Maurice · CIK 0001747753 · Director · President and CEO · 10% owner Vaccinex (Rochester), L.L.C. · CIK 0001747866 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The reported securities converted into shares of Common Stock on a 0.1641-for-1 basis immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.